µ²ºc¦¡ |
|
Trastuzumab emtansine
|
UpToDate |
UpToDate ³sµ²
|
ÃIJz§@¥Î |
|
Trastuzumab emtansine ¬OÂê©w HER2 ªº§ÜÅéÃĪ«½Æ¦XÅé¡C§ÜÅé¬O¤HÃþ§Ü HER2 IgG1¡Ð (trastuzumab)¡C¤p¤À¤l²ÓM¬r¯À DM1 ¬O·LºÞ§í¨î¾¯¡Cµ²¦X¨ì HER2 ¨üÅ骺²Ä IV ¤p°Ï«á¡A trastuzumab emtansine ¶}©l¥H¨üÅ鬰´C¤¶¶i¦æ¤º¤Æ¡A¤§«áªº·»酶Å鰸ѹLµ{Åý²ÓM¤ºÄÀ©ñ§t¦³ DM1 ªº²ÓM¬r©Ê¥NÁª«¡CDM1 µ²¦X¨ì·LºÞ³J¥Õ(tubulin)ªº¹Lµ{·|¯}Ãa²ÓM¤ºªº·LºÞºôµ¸¡A¾ÉP²ÓM©P´Áªýº¢»P²ÓMä¤`¡C¦¹¥~¡AÅé¥~¸ÕÅçÅã¥Ü¡Atrastuzumab emtansine »P trastuzumab Ãþ¦ü¡A¤]·|§í¨î HER2 ¨üÅé°T®§¶Ç»¼ªº¥\¯à¡A¤Þ°_§ÜÅé¨Ì¿à©Ê²ÓM´C¤¶ªº²ÓM¬r©Ê¡A¨Ã§í¨î HER2 ¹L«×ªí²{ªº¤HÃþ¨ÅÀù²ÓM¤ºªº HER2 M¥~°Ï²æ¸¨¡C
|
¾AÀ³¯g |
|
KADCYLA ³æ¿W¨Ï¥Î®É¯à°÷ªvÀø HER2 ¶§©Ê¡B¤§«e¤À§O±µ¨ü¹L trastuzumab »P¤@ºØ taxane ÃĪ«ªvÀø©Î¨ä¦X¨ÖÀøªkªºÂಾ©Ê¨ÅÀù¯f±w¡C »¡©ú: ¯f±wÀ³²Å¦X¤U¦C±ø¥ó¡G ¤§«e¤w¸g±µ¨ü¹LÂಾ©ÊÀù¯gªvÀø¡A©Î ¦b»²§UÀøªkªvÀø´Á¶¡©Î§¹¦¨ªvÀø«á 6 Ӥ뤺Àù¯g´_µo¡C
|
¥Îªk¥Î¶q |
|
KADCYLA «Øijªº¾¯¶q¬° 3.6 mg/kg¡A¨C 3 ¶g(¬°´Á 21 ¤Ñªº©P´Á)ÀR¯ß¿éª`¤@¦¸¡Aª½¨ì¯f±¡´c¤Æ©Î¥X²{µLªk±µ¨üªº¬r©Ê¬°¤î¡C½Ð¤Å¬I¥´°ª©ó 3.6 mg/kg ªº KADCYLA ¾¯¶q¡C½Ð¤Å¥H KADCYLA ¥N´À Trastuzumab ©Î Trastuzumab ¨ú¥N KADCYLA¡C ¦b¬I¥´ÃĪ«´Á¶¡¡A½Ð¥J²ÓºÊ´ú¿éª`³¡¦ì¥i¯à¥X²{ªº¥Ö¤U®û¼í¡C ²Ä 1 ¦¸¿éª`¡G¿éª` 90 ¤ÀÄÁ¡CÀ³¦b¿éª`¹Lµ{¤¤¤Î¬I¥´°_©l¾¯¶q¤§«á¦Ü¤Ö 90 ¤ÀÄÁ¤º¡AÆ[¹î¯f±w¬O§_¥X²{µo¿N¡B§NŸ©Î¨ä¥L¿éª`¬ÛÃöªº¤ÏÀ³¡C «áÄò¿éª`¡GY¤§«e¿éª`@¨ü±¡ªp³£«Ü¦n¡A½Ð¿éª` 30 ¤ÀÄÁ¡CÀ³¦b¿éª`¹Lµ{¤¤¤Î¿éª`«á¦Ü¤Ö 30 ¤ÀÄÁ¤ºÆ[¹î¯f±wªº¤ÏÀ³¡C
|
ÃİʤO¾Ç |
|
¤À§G ¦b±µªñ¿éª`µ²§ô®É¥iÆ[¹î¨ì ADC »P DM1 ªº³Ì¤j¿@«×(Cmax)¡C¸ÕÅç 1 ¤¤¡A¬I¥´ KADCYLA «á ADC »P DM1 ©ó²Ä 1 ©P´Áªº Cmax ¥§¡È(¼Ð·Ç®t)¤À§O¬° 83.4 (16.5) £gg/mL »P 4.61 (1.61) ng/mL¡C ¨Ì¾ÚÅé¥~¸ÕÅçµ²ªG¡A¥§¡¦³ 93%ªº DM1 µ²¦X¦Ü¤HÃþ¦å¼ß³J¥Õ¡C¨Ì¾ÚÅé¥~¸ÕÅçµ²ªG¡ADM1 ¬O P-glycoprotein (P-gp)¿}¤Æ³J¥Õ½èªº¨ü½è¡C¸sÅéÃĪ«°Ê¤O¾Ç¤ÀªRÅã¥Ü¡AADC ªº¤¤¥¡¤À¥¬Åé¿n¬° 3.13 L¡C ¥NÁ Åé¥~¸ÕÅçÅã¥Ü KADCYLA ªº¤p¤À¤l¦¨¤À DM1 ÂÇ¥Ñ CYP3A4/5 ¥NÁ¡CDM1 ¤£·|§í¨î©Î»¤¾ÉÅé¥~¥Dnªº CYP450 »Ã¯À¡C©óÁ{§É¸ÕÅ礤¤HÃþ¦å¼ß¤¤¶È¯à°»´ú¨ì§C¿@«×ªº trastuzumab emtansine ¥NÁª« MCC-DM1¡BLys-MCC-DM1 »P DM1¡C ±Æ°£ ¸sÅéÃĪ«°Ê¤O¾Ç¤ÀªRÅã¥Ü¡A¦bÀR¯ß¿éª` KADCYLA «á¡AADC ªº¹ø²M²v¬° 0.68 L/day¡A±Æ°£¥b°I´Á(t1/2)¤j¬ù 4 ¤Ñ¡C¨C 3 ¶g«½Æ³z¹LÀR¯ß¿éª`µ¹ÃÄ«á¡A¨Ã¥¼Æ[¹î¨ì KADCYLA ²Ö¿nªº±¡ªp¡C
|
°Æ§@¥Î |
|
¥i¯à¦³«K¯µ¡BÀYµh¡B°©Àf¦Ù¦×¯kµh¡Bäú¤ß¡B¯hªº±¡§Î¡C
|
¥æ¤¬§@¥Î |
|
©|¥¼°w¹ï KADCYLA ªºÃĪ«¥æ¤¬§@¥Î°õ¦æ¹L¥¿¦¡ªº¸ÕÅç¡CÅé¥~¸ÕÅçÅã¥Ü¡GKADCYLA ªº²ÓM¬r©Ê¦¨¤À DM1 ¥Dn¥Ñ CYP3A4 ¥NÁ¡A¤ñ¸û¤Ö¥Ñ CYP3A5 ¥NÁ¡CÀ³ÁקK¨Ö¥Î±j®Äªº CYP3A4 §í¨î¾¯(¨Ò¦p¡Gketoconazole¡Bitraconazole¡Bclarithromycin¡Batazanavir¡Bindinavir¡B nefazodone¡Bnelfinavir¡Britonavir¡Bsaquinavir¡Btelithromycin »P voriconazole)»P KADCYLA¡A¦]¬°¥i¯à¼W¥[ DM1 ªº¼ÉÅS¶q»P¬r©Ê¡C¥i¦Ò¼{¨ä¥L¹ï CYP3A4 ¤£²£¥Í§í¨î©Î§í¨î¥i¯à©Ê¸û§CªºÃĪ«¡C¦pªGµLªkÁקK¨Ö¥Î±j®Äªº CYP3A4 §í¨î¾¯¡A¦p¥i¦æ¡A½Ð¦Ò¼{©µ«á KADCYLA ªºªvÀø¡Aª½¨ìÅ餺´`Àô¨t²Î¤w¸g±Æ¥X±j®Äªº CYP3A4 §í¨î¾¯¬°¤î(¤j¬ù¬O§í¨î¾¯ªº 3 ӱư£¥b°I´Á)¡C¦pªGµLªk©µ«á¨Ö¥Î±j®Äªº CYP3A4 §í¨î¾¯»P KADCYLA ªvÀø¡A«hÀ³±K¤ÁºÊ´ú¯f±w¬O§_¥X²{¤£¨}¤ÏÀ³¡C
|
¸T§Ò |
|
µL¡C
|
µ¹¥I³W©w |
|
9.87.Trastuzumab emtansine (¦pKadcyla)¡G(110/2/1) 1.³æ¿W¨Ï¥Î©óHER2¹L«×ªí²{ (IHC3+©ÎFISH+)¤§Âಾ©Ê¨ÅÀù±wªÌ§@¬°¤G½uªvÀø¡A¥B¦P®É²Å¦X¤U¦C±¡§Î¡G (1)¤§«e¤À§O±µ¨ü¹Ltrastuzumab»P¤@ºØtaxaneÃĪ«ªvÀø¡A©Î¨ä¦X¨ÖÀøªk¡A©Îpertuzumab»Ptrastuzumab»P¤@ºØtaxaneÃĪ«ªvÀø¡C (2)¤§«e¤w¸g±µ¨ü¹LÂಾ©ÊÀù¯gªvÀø¡A©Î¦b»²§UÀøªkªvÀø´Á¶¡©Î§¹¦¨ªvÀø«á6Ӥ뤺Àù¯g´_µo¡C (3)¦X¨Ö¦³¥DnŦ¾¹(¤£¥]§t°©¤Î³n²Õ´)Âಾ¡C 2.¸g¨Æ«e¼f¬d®Öã«á¨Ï¥Î¡A®Öã«á¨C12¶g¶·À˪þÀø®Äµû¦ô¸ê®Æ¦A¦¸¥Ó½Ð¡AY¯e¯f¦³´c¤Æ±¡§Î§Y¤£À³¦A¦æ¥Ó½Ð¡A¨C¦ì¯f¤H¦Ü¦hµ¹¥I10Ó¤ë(13ÓÀøµ{¬°¤W)¡C 3.Trastuzumab emtansine©M lapatinib¶È¯à¾Ü¤@¨Ï¥Î¡A¤£±o¤¬´«¡C
|
ª`·N¨Æ¶µ |
|
°t»s«áªº·»²G¤£¥i§Ná¡C
±N°t»s«áªº trastuzumab emtansine ·»²Gª`¤J¸Ë¦³ 0.9%´â¤Æ¶uª`®g²G©Î 0.45%´â¤Æ¶uª`®g²Gªº»E´â¤A²m(PVC)¿éª`³U©Î¤£§t¨Å½¦¡B¤£§t PVC ªº»E²mÖL¿éª`³Uµ}ÄÀ¤§«á¡A¦b¨Ï¥Î«e¥i©ó 2-8¢XC ªº·Å«×¤U«O¦s¹F 24 ¤p®É¡C¦pªG¬O¥H 0.9%´â¤Æ¶uª`®g²Gµ}ÄÀ¡A¦s©ñ´Á¶¡¥i¯à·|¥X²{·L²Éª«½è¡A¦]¦¹¡A¿éª`§ëÃĮɥ²¶·¨Ï¥Î 0.2-0.22 ·L¦Ì¡B¤£·|§l¦¬³J¥Õ½èªº½u¤º»EîÅ碸(In-line non-protein adsorptive polyethersulfone)¹LÂo¾¹¡C
¤£¬Û®e©Ê ¤£¥i¨Ï¥Î¸²µå¿}(5%)·»²G¡A¦]¬°·|¾ÉP³J¥Õ½è¾®¶°¡C Trastuzumab emtansine ¤£¥i»P¨ä¥LÃĪ«²V¦X¨Ï¥Î©Î¥H¨ä¥LÃĪ«¶i¦æµ}ÄÀ¡C
|
ĵ»y |
|
¨xŦ¬r©Ê¡G¾Ú³q³ø¡A±µ¨ü KADCYLA ªvÀøªº¯f±w´¿µo¥ÍÄY«ªº¨xŦ¬r©Ê¡A¥]¬A¨xŦ°IºÜ»P¦º¤`¡C¦b¶}©l±µ¨ü KADCYLA ªvÀø¥H¤Î¬I¥´¨C¤@¾¯ KADCYLA ¤§«e¡A½ÐºÊ´ú¦å²MÂàÓi酶»PÁx¬õ¯À¿@«×¡CY¦å²MÂàÓi酶©ÎÁ`Áx¬õ¯À¿@«×¤É°ª¡A½Ð¾A·í´î¤Ö KADCYLA ¾¯¶q©Î°±¥Î KADCYLA¡C„h ¤ßŦ¬r©Ê¡G¬I¥´ KADCYLA ¥i¯à¾ÉP¥ª¤ß«Ç®g¥X²v(LVEF)´î¤Ö¡C¦b¶}©l KADCYLA ªvÀø«e¥H¤Î±µ¨ü KADCYLA ªvÀø´Á¶¡¡A½Ðµû¦ô©Ò¦³¯f±wªº¥ª¤ß«Ç¥\¯à¡CY¥ª¤ß«Ç¥\¯à¥X²{¨ã¦³Á{§É·N¸qªº°§C¡A½Ð¼È°±ªvÀø¡C„h FL-L¨à¬r©Ê¡G±µÄ²¨ì KADCYLA ¥i¯à¾ÉPFL-L¨à¦º¤`©Î¥ý¤Ñ¯Ê³´¡C½Ð§iª¾¯f±w¦³¤Wz·ÀI¦Ó¥B¥²¶·¦³®ÄÁ×¥¥¡C
|
¹L¶q³B²z |
|
°w¹ï¹L¶q¨Ï¥Î KADCYLA¡A¥Ø«eµL¤wª¾¸ÑÃÄ¡CÁ{§É¸ÕÅ礤¡A´¿³q³ø¹L KADCYLA ¹L¶q¨Ï¥Î(¬ù«Øij¾¯¶qªº¨â¿)¾ÉP²Ä 2 ¯Å¦å¤pªO´î¤Ö¯g(4 ¤Ñ«á½w¸Ñ)»P¤@¥ó¦º¤`ªº®×¨Ò¡C¦º¤`ªº®×¨Ò¤¤¡A¯f±w¿ù»~¦a±µ¨ü¨ì¾¯¶q 6 mg/kg ªº KADCYLA¡A¨Ã©ó¹L¶q«á¤j¬ù 3 ¶g¦º¤`¡F¦º¦]¤Î»P KADCYLA ¤§¶¡ªº¦]ªGÃö«Y¨Ã¥¼½T¥ß¡C
|
ÃÄ«~«O¦s¤è¦¡ |
|
½Ð±N¤p²~¸ËÃÄ«~Àx¦s©ó 2-8¢XC ªºÀô¹Ò¤¤¡C
¥HµLµßª`®g¥Î¤ô°t»sªº¤p²~¸ËÃÄ«~À³©ó°t»s«á¥ß§Y¨Ï¥Î¡CY¥¼¥ß§Y¨Ï¥Î¡A°t»s«áªº¤p²~¸ËÃÄ«~¥i©ó 2-8¢XC ªº·Å«×¤U«O¦s¹F 24 ¤p®É¡A¤§«á«h¥²¶·¥á±ó¡C
|